S. Sawai

Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.

Y. Tokunaga, A. Kagayama, J. Fujisaki, 1988, Chemical & pharmaceutical bulletin.

Liposomal sustained-release delivery systems for intravenous injection. I. Physicochemical and biological properties of newly synthesized lipophilic derivatives of mitomycin C.

Y. Tokunaga, A. Kagayama, J. Fujisaki, 1988, Chemical & pharmaceutical bulletin.

Liposomal sustained-release delivery systems for intravenous injection. III. Antitumor activity of lipophilic mitomycin C prodrug-bearing liposomes.

Y. Tokunaga, A. Kagayama, J. Fujisaki, 1988, Chemical & pharmaceutical bulletin.

Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes.

Y. Tokunaga, A. Kagayama, J. Fujisaki, 1988, Chemical & pharmaceutical bulletin.

Liposomal sustained-release delivery systems for intravenous injection V. Biological disposition of liposome-entrapped lipophilic prodrug of 1-beta-D-arabinofuranosylcytosine.

Y. Tokunaga, A. Kagayama, J. Fujisaki, 1988, Chemical & pharmaceutical bulletin.

Deactivation of a Cu/Al2O3 Catalyst in a N2O Decomposition Reaction

Katsutoshi Tanaka, A. Shimizu, M. Fujimori, 2003 .